Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2016 | Recognizing the heterogeneity of DLBCL

Laurie Sehn • 23 Sep 2016
iwNHL 2016
Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma Ibrutinib
PHOENIX

Laurie Sehn, MD of British Columbia Cancer Agency, Vancouver, Canada discusses the heterogeneity of diffuse large B-cell lymphoma (DLBCL). According to Dr Sehn, it is important to stop looking at DLBCL as one entity. A lot of ongoing trials are trying to recognize the heterogeneity of DLBCL and to tailor therapy based on biology. She mentions the PHOENIX trial (NCT01855750), which enrolled a group of patients with the non-germinal center B-cell subtype (GCB) subtype of DLBCL and asked whether adding ibrutinib to R-CHOP would be an advantage.
Recorded at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA.

More from Laurie Sehn

Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
12:15
CAR-T vs bispecific antibodies for lymphoma
David Maloney et al. • 17 Sep 2019
11:43
Will knowledge of the molecular pathology of lymphoma improve clinical trials?
David Maloney et al. • 17 Sep 2019
7:45
Novel targets and agents for lymphoma
John Kuruvilla et al. • 25 Sep 2018

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals